Bacteriophages as therapeutic agents
Level 5 - mechanism / opinion, no new human data
Narrative review / commentary discussing historical context and animal studies without original human clinical data.
OpenAlex W1975448026 · doi:10.3109/07853890108995959
What was done
This paper is a narrative overview summarizing the historical context of bacteriophage therapy (its global use in the 1930s–1940s and continued use in Eastern Europe and the former Soviet Union), its abandonment in Western medicine following the introduction of antibiotics, and findings from contemporary animal models.
What was found
The abstract provides no quantitative data or specific numerical endpoints. It reports qualitatively that bacteriophages can eliminate bacterial pathogens and that animal studies have shown promising results for treating bacterial infections.
Why it matters
As multidrug-resistant bacterial infections increase, understanding the therapeutic potential of bacteriophages highlights an alternative antimicrobial strategy that warrants modern, standardized clinical testing.
Limits
The abstract describes a non-systematic narrative perspective rather than a primary clinical trial or systematic review. It contains no human clinical outcome data, sample size details, or quantitative effect sizes.
Cited by
- context The pharmaceutical company Eli Lilly was founded as a bacteriophage company prior to the antibiotic era.